Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE7.1500
- TODAY'S CHANGE (%)0.0300 (0.4213%)
- Bid / Lots7.1300/ 2
- Ask / Lots7.2900/ 6
- Open / Previous Close7.0000 / 7.1200
- Day Range
- 52 Week Range
- Volume811,812
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 13311 | 7.12 |
| 09:34 ET | 100 | 7.15 |
| 09:36 ET | 3600 | 7.11 |
| 09:38 ET | 6884 | 7.11 |
| 09:39 ET | 8400 | 7.15 |
| 09:41 ET | 7638 | 7.22 |
| 09:43 ET | 13637 | 7.25 |
| 09:45 ET | 8197 | 7.25 |
| 09:48 ET | 2250 | 7.1701 |
| 09:50 ET | 10000 | 7.27 |
| 09:52 ET | 3026 | 7.2357 |
| 09:54 ET | 1910 | 7.31 |
| 09:56 ET | 3910 | 7.32 |
| 09:57 ET | 12159 | 7.31 |
| 09:59 ET | 3700 | 7.29 |
| 10:01 ET | 2948 | 7.33 |
| 10:03 ET | 1850 | 7.34 |
| 10:06 ET | 500 | 7.34 |
| 10:08 ET | 2172 | 7.37 |
| 10:10 ET | 5123 | 7.3725 |
| 10:12 ET | 2650 | 7.36 |
| 10:14 ET | 10775 | 7.3541 |
| 10:15 ET | 2290 | 7.31 |
| 10:17 ET | 713 | 7.2926 |
| 10:19 ET | 1390 | 7.335 |
| 10:21 ET | 650 | 7.3101 |
| 10:24 ET | 3100 | 7.33 |
| 10:26 ET | 200 | 7.33 |
| 10:28 ET | 1300 | 7.36 |
| 10:30 ET | 2128 | 7.33 |
| 10:32 ET | 3341 | 7.32 |
| 10:33 ET | 1159 | 7.32 |
| 10:35 ET | 903 | 7.32 |
| 10:37 ET | 1025 | 7.36 |
| 10:42 ET | 1100 | 7.35 |
| 10:44 ET | 300 | 7.35 |
| 10:46 ET | 27800 | 7.4 |
| 10:48 ET | 4914 | 7.45 |
| 10:50 ET | 1794 | 7.4701 |
| 10:51 ET | 19691 | 7.46 |
| 10:53 ET | 5194 | 7.41 |
| 10:55 ET | 1496 | 7.41 |
| 10:57 ET | 603 | 7.46 |
| 11:00 ET | 679 | 7.43 |
| 11:02 ET | 3123 | 7.42 |
| 11:04 ET | 7135 | 7.42 |
| 11:06 ET | 3995 | 7.3927 |
| 11:08 ET | 6800 | 7.4199 |
| 11:09 ET | 9004 | 7.514 |
| 11:11 ET | 3700 | 7.52 |
| 11:13 ET | 2539 | 7.44 |
| 11:15 ET | 3500 | 7.4 |
| 11:18 ET | 600 | 7.38 |
| 11:20 ET | 1500 | 7.41 |
| 11:22 ET | 495 | 7.4 |
| 11:24 ET | 1300 | 7.43 |
| 11:26 ET | 1434 | 7.44 |
| 11:27 ET | 3474 | 7.4092 |
| 11:29 ET | 5307 | 7.39 |
| 11:31 ET | 717 | 7.3999 |
| 11:36 ET | 4000 | 7.3601 |
| 11:38 ET | 1200 | 7.3 |
| 11:40 ET | 8503 | 7.19 |
| 11:42 ET | 4695 | 7.26 |
| 11:44 ET | 2300 | 7.23 |
| 11:47 ET | 2500 | 7.17 |
| 11:49 ET | 3986 | 7.185 |
| 11:54 ET | 1740 | 7.21 |
| 11:56 ET | 2985 | 7.24 |
| 11:58 ET | 500 | 7.24 |
| 12:00 ET | 600 | 7.26 |
| 12:05 ET | 2067 | 7.23 |
| 12:07 ET | 1303 | 7.22 |
| 12:09 ET | 100 | 7.22 |
| 12:12 ET | 1687 | 7.13 |
| 12:14 ET | 419 | 7.1873 |
| 12:20 ET | 700 | 7.1601 |
| 12:21 ET | 100 | 7.21 |
| 12:23 ET | 600 | 7.19 |
| 12:25 ET | 13447 | 7.13 |
| 12:27 ET | 600 | 7.14 |
| 12:30 ET | 1300 | 7.2 |
| 12:32 ET | 999 | 7.215 |
| 12:34 ET | 5189 | 7.17 |
| 12:36 ET | 4692 | 7.13 |
| 12:38 ET | 1009 | 7.1301 |
| 12:45 ET | 1200 | 7.13 |
| 12:48 ET | 337 | 7.15 |
| 12:50 ET | 4281 | 7.08 |
| 12:52 ET | 1495 | 7.11 |
| 12:54 ET | 19417 | 7.01 |
| 12:56 ET | 1382 | 7.04 |
| 12:57 ET | 1100 | 7.04 |
| 12:59 ET | 2435 | 7.05 |
| 01:01 ET | 1000 | 7.02 |
| 01:03 ET | 5188 | 7.035 |
| 01:06 ET | 1225 | 7.0205 |
| 01:08 ET | 2078 | 7.02 |
| 01:10 ET | 7155 | 6.9959 |
| 01:12 ET | 4656 | 6.9601 |
| 01:14 ET | 1181 | 6.95 |
| 01:15 ET | 22934 | 6.86 |
| 01:17 ET | 4550 | 6.919 |
| 01:19 ET | 558 | 6.92 |
| 01:21 ET | 1313 | 6.91 |
| 01:24 ET | 5215 | 6.88 |
| 01:26 ET | 19434 | 6.84 |
| 01:28 ET | 4887 | 6.8 |
| 01:30 ET | 750 | 6.8142 |
| 01:32 ET | 2400 | 6.82 |
| 01:33 ET | 3000 | 6.82 |
| 01:35 ET | 3944 | 6.8193 |
| 01:37 ET | 1987 | 6.8 |
| 01:42 ET | 1200 | 6.775 |
| 01:44 ET | 2151 | 6.78 |
| 01:46 ET | 2046 | 6.78 |
| 01:48 ET | 2000 | 6.8 |
| 01:50 ET | 1906 | 6.8 |
| 01:51 ET | 800 | 6.82 |
| 01:53 ET | 599 | 6.82 |
| 01:57 ET | 962 | 6.8061 |
| 02:00 ET | 524 | 6.8258 |
| 02:02 ET | 1600 | 6.795 |
| 02:04 ET | 6409 | 6.79 |
| 02:06 ET | 4099 | 6.795 |
| 02:08 ET | 2020 | 6.78 |
| 02:09 ET | 1700 | 6.82 |
| 02:11 ET | 955 | 6.79 |
| 02:13 ET | 100 | 6.7601 |
| 02:15 ET | 100 | 6.8 |
| 02:18 ET | 1390 | 6.79 |
| 02:20 ET | 2950 | 6.79 |
| 02:22 ET | 6588 | 6.8 |
| 02:24 ET | 9138 | 6.8 |
| 02:26 ET | 51479 | 6.9 |
| 02:27 ET | 4130 | 6.96 |
| 02:29 ET | 5022 | 6.96 |
| 02:31 ET | 3047 | 6.98 |
| 02:33 ET | 1215 | 6.98 |
| 02:36 ET | 3625 | 6.97 |
| 02:38 ET | 2446 | 6.98 |
| 02:40 ET | 1100 | 6.96 |
| 02:42 ET | 5741 | 7.0531 |
| 02:44 ET | 637 | 7.08 |
| 02:45 ET | 600 | 7.03 |
| 02:47 ET | 2000 | 7.02 |
| 02:49 ET | 700 | 7.05 |
| 02:51 ET | 900 | 7.04 |
| 02:54 ET | 2437 | 7 |
| 02:56 ET | 1100 | 6.97 |
| 02:58 ET | 850 | 6.96 |
| 03:00 ET | 2285 | 6.9801 |
| 03:02 ET | 600 | 6.98 |
| 03:03 ET | 1113 | 6.97 |
| 03:05 ET | 5569 | 7.06 |
| 03:07 ET | 800 | 7.07 |
| 03:09 ET | 3375 | 7.05 |
| 03:12 ET | 1195 | 7.02 |
| 03:14 ET | 7566 | 6.97 |
| 03:16 ET | 1900 | 7 |
| 03:18 ET | 3850 | 7 |
| 03:20 ET | 3050 | 6.98 |
| 03:21 ET | 4957 | 6.95 |
| 03:23 ET | 2230 | 6.97 |
| 03:25 ET | 4416 | 7.06 |
| 03:27 ET | 2703 | 7.07 |
| 03:30 ET | 1498 | 7.095 |
| 03:32 ET | 700 | 7.09 |
| 03:34 ET | 3000 | 7.11 |
| 03:36 ET | 9109 | 7.07 |
| 03:38 ET | 945 | 7.1 |
| 03:39 ET | 4900 | 7.13 |
| 03:41 ET | 500 | 7.15 |
| 03:43 ET | 2000 | 7.12 |
| 03:45 ET | 4115 | 7.105 |
| 03:48 ET | 3900 | 7.12 |
| 03:50 ET | 1500 | 7.13 |
| 03:52 ET | 5128 | 7.135 |
| 03:54 ET | 7702 | 7.15 |
| 03:56 ET | 5868 | 7.14 |
| 03:57 ET | 6399 | 7.1535 |
| 03:59 ET | 29815 | 7.15 |
Jun 3, 2024
May 30, 2024
DJ Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow JonesFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma, from 8:00AM ET on Thursday May 30, 2024 by Dow Jones
8:00AM ET on Thursday May 30, 2024 by Dow Jones
May 23, 2024
DJ Candel Therapeutics Shares Pop 39% After Lung-Cancer Treatment Yields Higher Survival in Trial, from 7:16PM ET on Thursday May 23, 2024 by Dow Jones
7:16PM ET on Thursday May 23, 2024 by Dow JonesCandel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting, from 5:00PM ET on Thursday May 23, 2024 by Dow Jones
5:00PM ET on Thursday May 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 239.1M | -5.5x | --- |
Eliem Therapeutics Inc | 239.4M | -16.6x | --- |
Actinium Pharmaceuticals Inc | 238.6M | -4.6x | --- |
Rani Therapeutics Holdings Inc | 235.5M | -3.4x | --- |
Aldeyra Therapeutics Inc | 243.0M | -7.6x | --- |
Monte Rosa Therapeutics Inc | 243.4M | -1.6x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $239.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
